Screener
Veracyte VCYT Product revenue — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Revenue: | ||
| Testing revenue | $135,091 | $107,309 |
| Product revenue | 3,679 | 3,580 |
| Biopharmaceutical and other revenue | 301 | 3,584 |
| Total revenue | 139,071 | 114,473 |
| Cost of revenue: | ||
| Cost of testing revenue | 33,306 | 28,260 |
| Cost of product revenue | 1,891 | 1,422 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's product revenue — total revenue?
- Veracyte (VCYT) reported product revenue — total revenue of $3.68M in Q1 2026.
- How has Veracyte's product revenue — total revenue changed year-over-year?
- Veracyte's product revenue — total revenue increased by 2.8% year-over-year, from $3.58M to $3.68M.
- What is the long-term trend for Veracyte's product revenue — total revenue?
- Over 4 years (2021 to 2025), Veracyte's product revenue — total revenue has grown at a 5.7% compound annual growth rate (CAGR), from $11.46M to $14.33M.
- What does product revenue — total revenue mean?
- This metric represents the total gross revenue generated specifically from the sale of products within the designated business segment. It serves as a primary indicator of the segment's market demand and top-line growth performance. Tracking this figure helps investors evaluate the scale and commercial success of the company's product-based offerings.
Ask your AI about Veracyte's product revenue — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude